Inovio Pharmaceuticals (GB:0A43)
NASDAQ:0A43
0A43 Stock Chart & Stats
$1.18
-$0.20(-8.69%)
At close: 4:00 PM EST
$1.18
-$0.20(-8.69%)
Day’s Range― - ―
52-Week Range$1.03 - $2.97
Previous CloseN/A
Volume92.09K
Average Volume (3M)87.63K
Market Cap
$90.50M
Enterprise Value$52.63M
Total Cash (Recent Filing)$37.68M
Total Debt (Recent Filing)$8.70M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Aug 12, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding82,273,240
10 Day Avg. Volume37,838
30 Day Avg. Volume87,632
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)33.86
Price to Sales (P/S)12485.24
P/FCF Ratio-9.18
Enterprise Value/Market Cap0.58
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-23.48
Enterprise Value/Ebitda-0.64
Forecast
1Y Price Target
$4.25Price Target Upside260.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.89
Revenue Forecast (FY)$8.90M
Bulls Say, Bears Say
Bulls Say
Regulatory Progress On INO-3107FDA acceptance of the INO‑3107 BLA with a defined PDUFA date creates a clear regulatory path toward potential accelerated approval. That structural milestone reduces long‑term binary risk, enables focused commercialization planning and partner engagement if approval is granted.
Strong Phase I/II Clinical EfficacyConsistent, large reductions in surgeries and favorable safety in Phase I/II imply meaningful clinical differentiation and probable label relevance. Durable efficacy and tolerability support physician adoption and payer coverage, underpinning a sustainable commercial market entry if approved.
Commercial Readiness And Product DifferentiationBuilt‑in logistical and administration advantages (no ultra‑cold chain, no surgery during dosing) plus prearranged commercial partners reduce rollout complexity. These structural advantages lower scaling costs and improve practical uptake versus products with higher handling or procedure burdens.
Bears Say
High Cash Burn And Limited RunwaySustained quarterly burn near $18M and a post‑offering runway only into Q1 2027 make the company persistently financing‑dependent. Ongoing reliance on capital raises risks dilution, distracts management, and constrains ability to fund confirmatory trials or commercialization without external funding.
Competitive Market Entry RiskA revenue‑generating first mover creates payer, physician and contracting precedents that raise switching costs. As a fast follower, Inovio faces tougher uptake dynamics, potential pricing/coverage pressure and the need for stronger real‑world differentiation to capture share.
Balance Sheet Deterioration And LeverageRecent TTM leverage, where debt exceeds equity, reduces financial flexibility and increases refinancing risk. Elevated leverage limits ability to self‑fund late‑stage trials or commercial launches, making the company more dependent on dilutive financing or partnerships over the medium term.
Inovio Pharmaceuticals News
0A43 FAQ
What was Inovio Pharmaceuticals’s price range in the past 12 months?
Inovio Pharmaceuticals lowest share price was $1.03 and its highest was $2.97 in the past 12 months.
What is Inovio Pharmaceuticals’s market cap?
Inovio Pharmaceuticals’s market cap is $90.50M.
When is Inovio Pharmaceuticals’s upcoming earnings report date?
Inovio Pharmaceuticals’s upcoming earnings report date is Aug 12, 2026 which is in 60 days.
How were Inovio Pharmaceuticals’s earnings last quarter?
Inovio Pharmaceuticals released its earnings results on May 13, 2026. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.35 by $0.07.
Is Inovio Pharmaceuticals overvalued?
According to Wall Street analysts Inovio Pharmaceuticals’s price is currently Undervalued.
Does Inovio Pharmaceuticals pay dividends?
Inovio Pharmaceuticals does not currently pay dividends.
What is Inovio Pharmaceuticals’s EPS estimate?
Inovio Pharmaceuticals’s EPS estimate is -0.24.
How many shares outstanding does Inovio Pharmaceuticals have?
Inovio Pharmaceuticals has 82,273,240 shares outstanding.
What happened to Inovio Pharmaceuticals’s price movement after its last earnings report?
Inovio Pharmaceuticals reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.35. Following the earnings report the stock price went up 6.107%.
Which hedge fund is a major shareholder of Inovio Pharmaceuticals?
Currently, no hedge funds are holding shares in GB:0A43
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inovio Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.25 (260.17% Upside)
$4.25 (260.17% Upside)
Blogger Sentiment
Bullish
GB:0A43 Sentiment 70%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.11%
12-Months-Change
Fundamentals
Return on Equity
-666.47%
Trailing 12-Months
Asset Growth
-42.96%
Trailing 12-Months
Company Description
Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.
0A43 Company Deck
0A43 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial progress on multiple fronts—regulatory milestones (BLA accepted, mid-cycle review with no new issues, PDUFA date set), strong Phase I/II efficacy/safety signals, commercial preparation and advancing partnerships—tempered by material near-term financial constraints (cash declined ~36%, an $18M estimated Q2 burn and runway into only Q1 2027), outstanding regulatory questions about accelerated approval eligibility and an active competitive landscape. Overall the tone was optimistic about the program and platform advancement but realistic about financing and regulatory uncertainties.View all GB:0A43 earnings summaries0A43 Stock 12 Month Forecast
Average Price Target
$4.25
▲(260.17% Upside)
Technical Analysis
Agenus
―
Oncolytics Biotech
―
―
Atossa Therapeutics
―
Anixa Biosciences
―
Instil Bio
―
Options Prices
Currently, No data available
---